Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Bora LimDavid A PotterMohamad A SalkeniPaula SilvermanTufia C HaddadFrederic ForgetAhmad AwadaJean-Luc CanonMichael DansoAlain LortholaryHughes BourgeoisElizabeth Tan-ChiuSylvie VincentBrittany BahamonKevin J GalinskyChirag PatelRachel NeuwirthE Jane LeonardJennifer R DiamondPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer.